Survival Outcomes and Treatment Strategies in Glioblastoma Multiforme

Glioblastoma multiforme remains the most aggressive and lethal primary brain tumour in adults, with median overall survival scarcely exceeding 15 months despite multimodal therapy. Standard management encompasses maximal safe resection followed by concurrent radiotherapy and temozolomide, yet almost all patients experience recurrence. Efforts to improve outcomes have focused on optimising chemoradiation regimens, prolonging adjuvant chemotherapy, integrating electric field therapies and developing targeted or immunomodulatory approaches. Population‐level studies indicate modest gains in two‐ and three‐year survival over the past two decades, but five‐year survival remains below 5 percent. Challenges include intratumoural heterogeneity, treatment resistance and the blood–brain barrier. Recent work has sought to refine patient selection, personalise treatment based on molecular markers and translate trial results into real‐world practice.

Research from Nature Portfolio

Recent meta‐analyses of population‐based studies demonstrate that the introduction of concurrent temozolomide with radiotherapy has doubled two‐ and three‐year survival rates for glioblastoma patients since 2005. Improvements in three‐year survival—from approximately 4 percent to over 10 percent—reflect more effective combination protocols and better supportive care. However, analyses reveal that five‐year survival remains static at around 4 percent, highlighting an unmet need for therapies that sustain long‐term tumour control. These findings underscore the importance of continued molecular characterisation of long‐term survivors and the development of novel agents capable of preventing late recurrences.

Survival Outcomes and Treatment Strategies in Glioblastoma Multiforme publication trend

The graph below shows the total number of articles in survival outcomes and treatment strategies in glioblastoma multiforme across all publications each year (not limited to Nature Index journals).

Technical terms

Overall survival (OS): the length of time from diagnosis or initiation of treatment until death from any cause.

Progression-free survival (PFS): the interval during and after treatment in which the patient lives without radiological or clinical evidence of tumour growth.

Temozolomide (TMZ): an oral alkylating chemotherapy agent forming the backbone of postoperative glioblastoma therapy.

Tumour-treating fields (TTFields): a modality employing alternating electric fields to disrupt mitosis in rapidly dividing tumour cells.

Antiangiogenic therapy: treatments that inhibit the formation of new blood vessels within the tumour microenvironment.

References

1. Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Scientific Reports (2020).
2. Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines (2021).
3. Nonsurgical treatment of recurrent glioblastoma. Current Oncology (2015).
4. Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?. Neuro-Oncology Advances (2021).